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Abstract We have recently designed potent 5 selective opioid 
antagonist dipeptides on the basis of a simple conformational 
analysis. Following a similar procedure we found a \i selective 
dipeptide antagonist, 2,6-dimethyl-Tyr-D-Phe-NH2. Although its 
selectivity is not as high as those of the quoted S selective 
dipeptides it has good in vitro activity and looks very promising 
for further development since the 2,6-dimethyl-Tyr-D-Phe 
message, like the 8 selective 2,6-dimethyl-Tyr-l,2,3,4-tetrahy-
droisoquinoline-3-carboxylic acid counterpart, seems able to 
impart antagonism to longer peptides. 
© 1997 Federation of European Biochemical Societies. 
Key words: Antagonism; Peptide; Opioid selectivity; 
Conformation 
1. Introduction 
Opioid antagonists are generally obtained by substitution of 
a proton of the basic nitrogen of the tyramine moiety, com-
mon to all opioids, with an appropriate substituent, generally 
an allyl or a cyclopropylmethyl group. The first exception to 
this rule was furnished by the discovery [1] of two 8 selective 
peptide antagonists related to dermorphin but containing L-
Tic (l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) in the 
second position: Tyr-Tic-Phe-NFÍ2 (dubbed TIP) and Tyr-
Tic-Phe-Phe-NHa (dubbed TIPP). 
On the basis of a simple conformational analysis [2] we 
have shown that the antagonism displayed by all [Tyr-Tic2] 
peptides can be attributed to the relative arrangement of the 
two aromatic rings of Tyr and Tic, i.e. to a specific two-res-
idue message domain represented by the sequence Tyr-Tic. 
The spatial relationship of these rings is very similar to the 
characteristic 90° arrangement assumed by the corresponding 
rings of several 8 selective naltrindole derivatives described by 
Portoghese and coworkers [3]. Our interpretation led to the 
synthesis of the first opioid dipeptide, Tyr-Tic-NH2 [2], and to 
a series of simple and very potent 8 selective antagonists con-
taining the related 2,6-dimethyl-Tyr (Tyr(Me)2) instead of Tyr 
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[4]. In fact, Tyr-Tic-NH2 itself behaves as a 8 selective antag-
onist [2] and even more significantly introduction of Tic in the 
second position of the sequence converts enkephalin, a non-
selective agonist, and dermorphin (a \x selective agonist) into 8 
selective antagonists [5]. The view of a specific 'antagonist 
message' was subsequently substantiated by the discovery of 
ultraselective 8 antagonists containing the Tyr(Me)2-Tic mes-
sage [4,6] and by the design of a rigid antagonist lacking the 
basic charge of tyramine [7]. 
The conformations of [Tyr-Tic] and/or [Tyr(Me)2-Tic] pep-
tides are greatly influenced by the conformational preferences 
of Tic. Since the amide nitrogen is part of a six-membered 
ring similar to that of pipecolic acid, the populations of con-
formers containing a cis peptide bond are comparable to those 
of conformers containing trans peptide bonds. In addition, the 
Tic side chain conformation is confined to the single value of 
X1 imposed by cyclization, a circumstance drastically different 
from the conformational freedom typical of aromatic amino 
acid residues. Thus, the conformations accessible to Tyr-Tic 
peptides, notably the Clb+ eis conformer we previously iden-
tified [2] as a likely 8 selective bioactive conformation, are 
forbidden or severely disfavored for opioid peptides contain-
ing an aromatic amino acid residue in the second position. 
We decided to explore the conformational preferences (and 
possible biological activity) of peptides containing a aromatic 
amino acid residue (Xaa) in the second position, i.e. Phe, Tyr, 
Trp or His, since it is likely that other relative arrangements 
accessible to Tyr-Xaa, although not ideal for 8 selectivity, may 
confer to the peptides good opioid activity and a different 
selectivity. The starting choice of this systematic search was 
Phe for the second residue (Xaa), because Tic was originally 
derived from this amino acid residue. Instead of Tyr we de-
cided to use Tyr(Me)2 as the first residue for all peptides since 
it ensures a far better binding without departing too much 
from the constitution of the parent residue (Tyr). 
Based on a detailed conformational analysis of the model 
dipeptides Tyr(Me)2-Phe-NHCH3 and Tyr(Me)2-D-Phe-
NHCH3 that cover the entire range of chiral isomers corre-
sponding to Tyr(Me)2-Phe, here we present the synthesis and 
biological properties of new \i selective opioid peptide antag-
onists characterized by a message domain of only two residues 
and by the absence of derivatization on the basic nitrogen. 
2. Materials and methods 
Tyr(Me)2 (2',6'-dimethyl-L-tyrosine) was a generous gift of J.H. 
Dygos (Searle and Co.). The racemic mixture of Tyr(Me)2 was pre-
pared as described in [8]. All peptides were prepared by solid phase 
peptide synthesis with a Milligen 9050 synthesizer using a (4-(2',4'-
dimethoxyphenyl)-Fmoc-aminomethyl-phenoxy resin (Rink amide 
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MBHA resin) (0.55 mmol/g; 0.2 g in all syntheses) (Novabiochem 
AG). The resin was mixed with glass beads (1:15 w/w) (Sigma). Pep-
tides were assembled using Fmoc protected amino acids (4-fold ex-
cess) (Novabiochem AG), 1,3-diisopropylcarbodiimide (DIPCDI, 4-
fold excess) and 1-hydroxybenzotriazole (HOBt, 4-fold excess) as cou-
pling agents (1 h for each coupling). Tyr(Me)2 and i7D-Tyr(Me)2 were 
protected as Boc and the side chain were left unprotected. Crude 
deprotected peptides (88% CF3COOH, 5% H20 and 7% triethylsilane) 
were purified by preparative HPLC. The synthetic peptides were ho-
mogeneous as assessed by analytical HPLC and TLC; amino acid 
analysis and NMR properties were consistent with the peptide se-
quence and purity was > 98%. D-Tyr(Me)2 containing peptides were 
prepared starting from the racemic mixture of Tyr(Me)2 and diaster-
eoisomeric peptides were separated by preparative HPLC and identi-
fied by comparison with an authentic sample of L-Tyr(Me)2 contain-
ing peptides. 
2.1. Biological tests 
2.1.1. Radioreceptor assays. Rat brain membrane synaptosomes 
(P2 fraction) were prepared as described by Salvadori et al. [9]. The 
S and u receptor binding sites were specifically labeled using 
[3H]DPDPE (34.3 Ci/mmol) and [3H]DAGO (60 Ci/mmol) respec-
tively [10]. Competitive displacement assays were incubated for 2 h 
at room temperature (22-23°C); rapid filtration onto glass fiber filters 
and washing of the membranes occurred within 5 s. All assays were 
conducted in duplicate with 7-12 dosage points and using three syn-
aptosomal preparations; repetitions (n values) are given in Table 1 
together with AJ/nM determined according to Cheng and Prusoff [11]. 
2.1.2. Bioassays. Transmurally stimulated guinea pig ileum (GPI). 
Guinea pigs were killed with C0 2 and bled. Sections of GPI were 
prepared as described previously [12]. Segments of ileum 2-3 cm 
long were placed in a 10 ml organ bath containing Tyrode's solution 
with 5% CO2 in 95% oxygen maintained at 37°C. The ileum prepa-
ration was placed between platinum electrodes and connected to a 85/ 
2/50 MARB stimulator. A force displacement transducer and unire-
cord model polygraph were used for measurement of isotonic contrac-
tion. A resting tension of 0.5 g was applied and after a 30 min equi-
libration period, the preparation was stimulated with a 0.5 ms pulse 
delivered transmurally at a frequency of 10 s at supramaximal voltage 
(25 V). Under these conditions, the preparation allows a contraction 
mean of 60 mm ± 0.57. The inhibition of ileal contractions by drugs 
was expressed as percentage of basal value (mean ± S.E.M.). Each 
analog was tested for its ability to inhibit electrically evoked contrac-
tions (i.e. tested for agonist activity) and to antagonize the inhibitory 
effects of |x agonists (DAGO, morphine, dermorphin). p^42 values 
were calculated according to the procedure reported by Tallarida 
and Murray [13]. 
Rabbit jejunum (RJ) preparation. This is a new in vitro model to 
study 8 opioid activity that we prefer to the customary MVD assay 
since the jejunum contains mainly 8 receptors [14-16] whereas MVD 
also contains |i and K receptors [17,18]. The preparation of rabbit 
jejunum was according to Valeri et al. [14]. The animals were killed 
with CO2 and bled. The abdomen was opened with a midline incision 
and three or four segments of jejunum (3 cm long) were removed from 
the same animal and placed in 10 ml tissue baths containing Tyrode's 
solution. The tissues were connected to an isotonic transducer by 1 g 
loading and allowed to equilibrate for 45 min; during this period 
regular spontaneous activity was recorded. Under these conditions, 
the preparation showed a contraction mean of 60 mm±0.57, and 
the inhibition of rabbit contractions by the standard 8 agonist [D-
Ala2] deltorphin II was as reported by Guerrini et al. [15]. 
Molecular mechanics (MM). MM calculations were based on the all 
atoms parametrization of the AMBER force field [19,20] as imple-
mented in the SYBYL package. EM calculations were performed 
with a distance dependent dielectric constant (e=r) and no distance 
cut-off for non-bonded interactions. 
3. Results and discussion 
As already done in the design of S selective antagonists 
containing the Tyr-Tic message [2], in order to limit the syn-
thetic efforts we performed a conformational analysis of pep-
tides containing the initial Tyr(Me)2-Phe sequence and com-
pared the resulting energy minima with appropriate rigid 
compounds. The choice for a 8 selective mold is easy since 
all naltrindole analogs described by Portoghese et al. [3,21] are 
suitable candidates. In the present work we used M e N T I as 
already done for the [Tyr-Tic] [2,5] and [Tyr(Me)2-Tic] pep-
tides [4,6]. 
The choice of an appropriate \i selective mold is more diffi-
cult since most u\ selective opioids derived from alkaloids have 
but one aromatic ring (i.e. that of tyramine). In our case, to 
have a meaningful comparison with the Tyr(Me)2-Phe se-
quence, we wanted to have a rigid mold with two aromatic 
rings. A reasonable compromise is to use some of the many 
synthetic K opioids that have fairly low K!\I selectivity. In 
particular we chose oAf-cinnamoyl-ß-naltrexamine (CNX) for 
which the ratio of (A"¡)Kl to (Ki)n is 0.2/0.07, i.e. slightly in 
favor of ¡a. [22], and ICI 199441 [23], which is more K selective. 
We selected the model dipeptides Tyr(Me) 2 -Phe-NHCH 3 
and Tyr(Me)2-D-Phe-NHCH3 as representative of all possible 
chiral isomers of the Tyr(Me)2-Phe message, i.e. Tyr(Me)2-
Phe, D-Tyr(Me)2-D-Phe, D-Tyr(Me)2-Phe and Tyr(Me)2-D-
Phe. This is rigorously true if we deal with dipeptides only, 
whereas all four possibilities should be taken into account in 
the case of longer peptides. However, it is safe to assume that 
the conformational preferences of the two initial residues are 
predominant for receptor selectivity, particularly if the C-ter-
minal sequences contain no aromatic residue. Accordingly we 
performed a detailed energy calculation only for the quoted 
dipeptides Tyr(Me) 2 -Phe-NHCH 3 and Tyr(Me)2-D-Phe-
N H C H 3 , whose preferences also correspond to D-Tyr(Me)2-
D-Phe-NHCH3 and D-Tyr(Me)2-Phe-NHCH3 respectively. 
Table 1 
Binding and functional bioactivity8 of [Tyr(Me)2-Phe] peptides 
Peptide KilnM 
8 
KilnM GPIb 
pA2 
Tyr(Me)2-Phe-NH2 
D-Tyr(Me)2-Phe-NH2 
Tyr(Me)2-D-Phe-NH2 
D-Tyr(Me)2-D-Phe-NH2 
Tyr(Me)2 -Phe-G-V-V-NH2 
D-Tyr(Me)2-Phe-G-V-V-NH2 
Ty r(Me)2 -D-Phe-G-V- V-NH2 
D-Tyr(Me)2-D-Phe-G-V-V-NH2 
386.5 ± 52 (3) 
19771412 (5) 
15.5 ±1.1 (4) 
2543 ± 334 (4) 
118.3 ±22 (4) 
246.6 ±55 (5) 
2.32 ±0.5 (5) 
22.3 ± 5.6 (5) 
209.6 ±48 (3) 
866.4 ±141 (4) 
3.56 ±0.4 (3) 
501 ±92 (4) 
75.3 ± 8.8 (4) 
113.8 ±18 (3) 
0.53 ±0.08 (3) 
2.1 ±0.4 (3) 
1 
i 
7.2; 
4.9 
5.7 
5 
7.3; 
5.2 
7.0e; 6.5d 
7.2e; 6.7d 
aAU compounds were inactive on the RJ at concentrations > 10~4 M. 
u, antagonism measured in relation to: bDAGO, cmorphine or ddermorphin; 
i=inactive at concentrations > 10~4 M. 
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Fig. 1. Energy maps of Tyr(Me)2-Phe-NHCH3 (left) and Tyr(Me)2-D-Phe-NHCH3 (right). The energy (kcal/mol) is plotted as a function of \j/L 
and 02. The energy levels are indicated by the legend at the bottom of the figure. 
A complete conformational search for a dipeptide presents 
no technical problems; we performed complete searches for 
our dipeptides using intervals of 10° for all relevant internal 
rotation angles, i.e. %l\, v|/i, <|)2, v|/2 and %x2. Other internal 
coordinates were minimized at each step. However, in the 
representation of the results it is convenient to describe the 
conformers as a function of only two internal coordinates, i.e. 
\\>i and fa. These two internal coordinates were chosen as 
most representative to describe the conformational preferen-
ces of the dipeptides, since they are the central rotation angles. 
Fig. 1 shows that the energy map of Tyr(Me)2-Phe-NHCH3 as 
a function of \\>i and 02 is characterized by one broad mini-
mum centered approximately at 160/—80 (a). The energy map 
of Tyr(Me)2-D-Phe-NHCH3 on the other hand shows three 
distinct minima of comparable energy centered at 150/60 (i), 
150/-60 (ii) and -60/90 (iii). 
In spite of the similarity of most of the internal coordinates 
of the absolute minimum (a) of Tyr(Me)2-Phe-NHCH3 with 
those of the Tlb+ conformer of Tyr-Tic-NH2, none of these 
minima (a, i-iii) gave a satisfactory overlap with MeNTI. This 
finding may be viewed as an indirect confirmation that the 
bioactive conformation for 8 selective dipeptides corresponds 
to the eis Clb+ conformer of Tyr-Tic-NH2, which however is 
not energetically accessible to Tyr(Me)2-Phe-NHCH3. On the 
other hand, minima (iii) and to a lesser extent (ii) have a fairly 
good overlay with the molecular model of CNX whereas min-
ima (i) and to a lesser extent (ii) have a fairly good overlay 
with the molecular model of ICI 199441. The fact that the fit 
is not perfect, particularly at the basic nitrogen and the second 
aromatic ring (distinct from that of tyramine), hints that high 
agonist activity may be prevented whereas antagonism is still 
likely [7]. 
Based on this conformational analysis we synthesized the 
simple dipeptides Tyr(Me)2-D-Phe-NH2 and Tyr(Me)2-Phe-
NH2 and two analogs containing the same messages but a 
longer, hydrophobic address sequence, i.e. Tyr(Me)2-D-Phe-
Gly-Val-Val-NH2 and Tyr(Me)2-Phe-Gly-Val-Val-NH2. Table 
1 summarizes the binding data and in vitro activity of these 
peptides. For comparison, the binding data of the correspond-
ing D-Tyr(Me)2-Phe and D-Tyr(Me)2-D-Phe peptides are also 
reported. 
All compounds show some preference for |0. vs. 5 opioid 
receptors, and all pentapeptides have better opioid receptor 
binding than the corresponding dipeptides, i.e. C-terminal 
elongation with hydrophobic residues (Val-Val) improves 
binding at both \i and 8 opioid receptors. These data are 
somewhat surprising if compared to the behavior of peptides 
containing the Tyr-D-Xaa-Phe (Xaa = Ala, Met, Leu) typical 
of amphibian opioid peptides, in which changing the chirality 
of the second residue leads to a drastic decrease of affinity to 
opioid receptors. 
On the other hand, it is very interesting to observe that, 
similar to what we have recently reported for 8 selective an-
tagonists [2], a simple dipeptide sequence can behave as a kind 
of 'antagonist message'. In fact, although all compounds are 
inactive as agonists in the GPI assay at concentrations > 10~4 
M, consistent with binding data the two compounds with a L-
Tyr(Me)2-D-Phe chirality message have pyl2s ranging from 6.5 
to 7.3, depending on the \i agonist used. Intrinsic activity does 
not change from the dipeptide, Tyr(Me)2-D-Phe-NH2 to the 
pentapeptide Tyr(Me)2-D-Phe-Gly-Val-Val-NH2 in the stimu-
lated GPI tissue. On the other hand, all compounds are in-
active in the tissue containing 8 opioid receptors (RJ) at con-
centrations > 10~4 M. These compounds can be considered 
neither 8 agonists nor 8 antagonists since the typical values for 
RJ are an IC50 of 730 nM in the case of the 8 agonist [D-Ala2] 
deltorphin II [15] and a p^42 of 7.2 for the 8 antagonist nal-
trindole (unpublished results). This behavior is particularly 
surprising for the Tyr(Me)2-D-Phe di- and pentapeptide that 
bind to 8 receptors with K[ values of 15.5 and 2.32 nM re-
spectively. 
The \i opioid antagonist activity of the dipeptide is remark-
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able also considering that the only known \i antagonist of 
peptide structure, i.e. H-D-Phe-c(Cys-Tyr-D-Trp-Arg-Thr-
Pen)-Thr-NH2 (p^2 = 6.4 -=- 7.9), a cyclic octapeptide derived 
from somatostatin [24], contains the Tyr-D-Trp motif in its 
sequence. The fairly small it selectivity is not too surprising 
if one takes into account the role of a further locus of inter-
action (different from the two aromatic residues) present in 
longer peptides [25,26]. However, the recent discovery of a 
very selective \i agonist tetrapeptide [27] hints that the search 
for short selective peptides is still realistic. Owing to its simple 
chemical constitution Tyr(Me)2-D-Phe-NH2 looks to be a very 
promising it antagonist both as a lead structure and for prac-
tical applications. 
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